SXTP Stock Forecast & Price Target

60 Degrees is facing challenges in meeting its projected revenue growth, with Q1 FY26 sales falling short of expectations and a lack of visibility on future pipeline programs. Additionally, the company has a low cash balance and may need to raise additional financing in the near future. However, there is still potential for success with the commercialization of ARAKODA and the addition of the Australian Chestnut extract program to their pipeline. Overall, there is potential for long-term growth and success, but the current financial constraints and lack of visibility warrant a Neutral rating from a third person perspective.

60 Degrees is facing challenges with their product revenue due to higher returns and lower sell-through, leading to a decline in quarterly run-rate and pharmacy sales. The company's positive cash position has been improved through ATM raises, but a continuous need for financing raises concerns. As a result, the PT has been adjusted downward to $4.20, factoring in potential dilution and low visibility on regulatory approvals for new indications.